Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XPKVR
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
DM002
|
|||||
| Synonyms |
DM002; DM002 (Doma); BCG012
Click to Show/Hide
|
|||||
| Organization |
Biocytogen (Originator);Sidao Medicine
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-HER3/Muc1 bsAb
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-3 (ERBB3); Mucin-1 (MUC1)
|
Antigen Info | ||||
| Payload Name |
BCPT02
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Hydrophilic, protease-cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
BLD1102
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
ADC-specific functional property(2027 Update)
Binding Affinity
| Dissocation Constant (Kd) | Binding Target | Description | Reference |
|---|---|---|---|
| 10 nM |
MUC1
|
DM002 is cross-reactive to human and cynomolgus monkey targets with an affinity (KD) of approximately 10-8 M.
|
[1]
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligible patients (≥18 years, ECOG 0-2, life expectancy ≥3 months) must have measurable disease (RECIST 1.1), adequate organ function
|
||||
| Administration Dosage |
An IV infusion of DM002 will be administrated approximately 30-60 min on D1 once Q3W
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06751329 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors | ||||
| Primary Endpoint |
Safety assessment includes DLT evaluation (grade 3 neurological/grade 4 toxicities) and MTD determination (0/3 or 1/6 DLT rate) for DM002 over 12 months.
|
||||
| Other Endpoint |
PK parameters (AUC, Cmax, Tmax, Ctrough) and efficacy (ORR per RECIST 1.1) will be analyzed for 12 months.
|
||||
References